Gilead is charged with "inflated" price of hepatitis C drugs

Source: Ding Xiangyuan filed a class action lawsuit against the Philadelphia transportation authority on December 12, 2014, alleging that the price of heavy hepatitis C drug sovaldi of Gilead science company was "inflated" On December 9, the southeast Pennsylvania Transportation Authority filed the lawsuit with the Philadelphia Federal Court for an unknown amount of compensation Sovaldi is a very effective drug for the treatment of hepatitis C It costs US $1000 per pill in the United States A typical course of treatment is 12 weeks and costs US $84000 In some other countries, the price of the drug is much lower According to the lawsuit, Gilead's pricing is an abuse of drug patent monopoly and violates the federal anti-monopoly law The suit also said Geely "has limited rights as a patent holder, and it cannot use patents to raise prices to defraud consumers." The Transportation Authority said it had paid more than $2.4 million to provide employees with sovaldi, and it was trying to represent a group of people who had already purchased sovaldi in the United States or could not afford the price it needed Sovaldi has generated more than $8.5 billion in revenue for Gilead in the first three quarters of 2014, almost half of the company's total sales Geely did not immediately respond to an email requesting comment on the matter The case was brought by the southeast Pennsylvania transportation authority, independently and on behalf of all other similar cases The defendant, Gilead science, was accepted by the District Court of the Eastern District of Pennsylvania, United States of America, No 2 document: 14-cv-06978.